Avid Bioservices Inc (CDMO)

[freethemice]

Entdoc, I think too much is made of this. Rituximab is a chimeric mAb that was approved 15 years ago
and is still going strong. It gained approval two years ago for maintenance therapy for follicular lymphoma.
http://en.wikipedia.org/wiki/Rituximab
I think if bavi + docetaxel is actually working to stop metastasis, as it seems to be doing in second-line NSCLC,
it is working against small tumors already. I think what is going on is that the primary tumors are stable and
the treatment is preventing the small tumors which start in other organs from growing into larger tumors.